Physician profile
Ann Thomas
NPI 1821061607
$5,183.69
in general payments reported to CMS, 2019-2025
39 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $112 · 2021: $647 · 2022: $517 · 2023: $632 · 2024: $1,310 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,475 · Education: $93.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.35 |
| Education | $93.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $600.19 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $566.83 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $479.31 | 2023-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $341.98 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $260.52 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $248.14 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $230.64 | 2025 | |
| Horizon Therapeutics Plc | $215.23 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $213.82 | 2021-2025 | Acthar |
| Calliditas Therapeutics US INC. | $213.05 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $190.38 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $188.68 | 2019-2023 | Korsuva, Veltassa |
| Novo Nordisk INC | $179.33 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $159.13 | 2021-2025 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $146.99 | 2024-2025 | Ibsrela |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.